Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cor and Schering sign $120mm Integrilin deal; restructured

Executive Summary

Cor Therapeutics (cardiovascular therapeutics) and Schering-Plough will co-develop and market Cor's Phase III platelet aggregation inhibitor Integrilin, in a deal that could be worth over $120 million to Cor.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Royalty or Profit Split Information
    • Co-Promotion
    • Reverse Licensing